Excimer Laser, Serum Markers & Psoriasis
Last updated on April 2022Recruitment
- Recruitment Status
- Withdrawn
- Estimated Enrollment
- 24
Inclusion Criteria
- Has been off topical therapies (e.g. calcipotriene, topical steroids) for at least 2 weeks
- Age 18 years and older
- Has been off systemic psoriasis therapies (e.g. retinoids, methotrexate, biologic agents, etc) for at least 4 weeks
- ...
- Has been off topical therapies (e.g. calcipotriene, topical steroids) for at least 2 weeks
- Age 18 years and older
- Has been off systemic psoriasis therapies (e.g. retinoids, methotrexate, biologic agents, etc) for at least 4 weeks
- Fitzpatrick Skin Types I-VI
- Male or female with diagnosis of psoriasis
- Psoriasis involvement of 5-15% BSA
Exclusion Criteria
- Any medical condition that could be aggravated or may cause extreme discomfort during the study period.
- Any suspicion that the psoriasis is of the photosensitive variant.
- Active history of photosensitivity (e.g. xeroderma pigmentosum, lupus erythematosus, porphyria, severe polymorphous light eruption, solar urticaria)
- Any medical condition that could be aggravated or may cause extreme discomfort during the study period.
- Any suspicion that the psoriasis is of the photosensitive variant.
- Active history of photosensitivity (e.g. xeroderma pigmentosum, lupus erythematosus, porphyria, severe polymorphous light eruption, solar urticaria)
Summary
- Conditions
- Psoriasis
- Type
- Interventional
- Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Subjects will undergo Excimer treatment twice a week until they reach a PASI 75 improvement, or until they reach the maximum of 20 total treatments. A blood draw to assess serum inflammatory markers will be performed at the screening visit and final visit. Chromameter assessment, photographs, PASI a...
Subjects will undergo Excimer treatment twice a week until they reach a PASI 75 improvement, or until they reach the maximum of 20 total treatments. A blood draw to assess serum inflammatory markers will be performed at the screening visit and final visit. Chromameter assessment, photographs, PASI and PGA (Physician Global Assessment) will be performed throughout the study to monitor psoriasis improvement, hyperpigmentation and erythema.
Inclusion Criteria
- Has been off topical therapies (e.g. calcipotriene, topical steroids) for at least 2 weeks
- Age 18 years and older
- Has been off systemic psoriasis therapies (e.g. retinoids, methotrexate, biologic agents, etc) for at least 4 weeks
- ...
- Has been off topical therapies (e.g. calcipotriene, topical steroids) for at least 2 weeks
- Age 18 years and older
- Has been off systemic psoriasis therapies (e.g. retinoids, methotrexate, biologic agents, etc) for at least 4 weeks
- Fitzpatrick Skin Types I-VI
- Male or female with diagnosis of psoriasis
- Psoriasis involvement of 5-15% BSA
Exclusion Criteria
- Any medical condition that could be aggravated or may cause extreme discomfort during the study period.
- Any suspicion that the psoriasis is of the photosensitive variant.
- Active history of photosensitivity (e.g. xeroderma pigmentosum, lupus erythematosus, porphyria, severe polymorphous light eruption, solar urticaria)
- Any medical condition that could be aggravated or may cause extreme discomfort during the study period.
- Any suspicion that the psoriasis is of the photosensitive variant.
- Active history of photosensitivity (e.g. xeroderma pigmentosum, lupus erythematosus, porphyria, severe polymorphous light eruption, solar urticaria)
Tracking Information
- NCT #
- NCT02165657
- Collaborators
- Photomedex
- Investigators
- Principal Investigator: Margaret Bobonich, NP University Hospitals Cleveland Medical Center
- Margaret Bobonich, NP University Hospitals Cleveland Medical Center
Get Well Soon